1914993-95-5
1914993-95-5 structure
- Name: GMI-1271
- Chemical Name: Sodium (1R,2R,3S,5R)-2-[(6-deoxy-α-L-galactopyranosyl)oxy]-3-ethyl-5-[(38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-yl)carbamoyl]cyclohexyl 2-acetamido-3-O-[(1S)-1-carboxylato-2-cyclohexylethyl]-2-deoxy-β-D-galactopyranoside
- CAS Number: 1914993-95-5
- Molecular Formula: C60H108N3NaO27
- Molecular Weight: 1326.493
- Catalog: Signaling Pathways Cytoskeleton Integrin
- Create Date: 2020-01-12 09:58:50
- Modify Date: 2025-08-24 19:26:36
-
A novel specific glycomimetic E-Selectin antagonist with Kd of 0.46 uM, IC50 of 1.75 uM; weakly inhibits L-selectin (IC50=2.9 uM) and >10 uM for P-selectin; not only mobilizes AML cells out of protective niches but also blocks NF-kB activation and prevents this E-selectin-mediated chemoresistance, thereby enhancing the therapeutic effects of standard chemotherapy; also overcomes MM metastasis and chemoresistance. Blood Cancer Phase 2 Clinical
| Name | Sodium (1R,2R,3S,5R)-2-[(6-deoxy-α-L-galactopyranosyl)oxy]-3-ethyl-5-[(38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-yl)carbamoyl]cyclohexyl 2-acetamido-3-O-[(1S)-1-carboxylato-2-cyclohexylethyl]-2-deoxy-β-D-galactopyranoside |
|---|---|
| Synonyms |
Sodium (1R,2R,3S,5R)-2-[(6-deoxy-α-L-galactopyranosyl)oxy]-3-ethyl-5-[(38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-yl)carbamoyl]cyclohexyl 2-acetamido-3-O-[(1S)-1-car boxylato-2-cyclohexylethyl]-2-deoxy-β-D-galactopyranoside
β-D-Galactopyranoside, (1R,2R,3S,5R)-2-[(6-deoxy-α-L-galactopyranosyl)oxy]-5-(1,6-dioxo-9,12,15,18,21,24,27,30,33,36,39,42-dodecaoxa-2,5-diazatritetracont-1-yl)-3-ethylcyclohexyl 2-(acetylamino )-3-O-[(1S)-1-carboxy-2-cyclohexylethyl]-2-deoxy-, sodium salt (1:1) |
| Description | A novel specific glycomimetic E-Selectin antagonist with Kd of 0.46 uM, IC50 of 1.75 uM; weakly inhibits L-selectin (IC50=2.9 uM) and >10 uM for P-selectin; not only mobilizes AML cells out of protective niches but also blocks NF-kB activation and prevents this E-selectin-mediated chemoresistance, thereby enhancing the therapeutic effects of standard chemotherapy; also overcomes MM metastasis and chemoresistance. Blood Cancer Phase 2 Clinical |
|---|---|
| References | References 1. Price TT, et al. Mol Cell Oncol. 2016 Jul 26;4(4):e1214771. 2. Culmer DL, et al. Thromb Haemost. 2017 Jun 2;117(6):1171-1181. 3. Natoni A, et al. Leukemia. 2017 Apr 25. doi: 10.1038/leu.2017.123. 4. Dutta P, et al. Arterioscler Thromb Vasc Biol. 2016 Sep;36(9):1802-8. View Related Products by Target Selectin Blood Cancer |
| Molecular Formula | C60H108N3NaO27 |
|---|---|
| Molecular Weight | 1326.493 |
| Exact Mass | 1325.706787 |